Actively Recruiting
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Led by Shanghai Junshi Bioscience Co., Ltd. · Updated on 2025-02-28
185
Participants Needed
1
Research Sites
196 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to compare JS004 plus Toripalimab with Investigator-Selected Chemotherapy in Patients with PD-(L)1 monoclonal antibody refractory Classic Hodgkin Lymphoma (cHL)
CONDITIONS
Official Title
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age at least 18 years old
- Both males and females are eligible
- Pathologically confirmed classical Hodgkin Lymphoma (cHL) with relapsed or refractory status
- Disease progression after achieving CR/PR in recent treatment or failure to achieve CR/PR
- Exhausted all standard treatments and refractory to PD-(L)1 monoclonal antibody
- ECOG performance status 0-2
- At least one measurable lesion meeting Lugano 2014 criteria
You will not qualify if you...
- Known allergy or contraindication to the investigational drug or its components
- Permanent discontinuation of anti-PD-(L)1 antibody due to immune-related adverse reactions
- Presence of central nervous system metastasis
- Presence of pleural effusion, ascites, or pericardial effusion requiring intervention
- Active autoimmune diseases requiring systemic treatment within the past 2 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
Y
Yuqin Song, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here